Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis
European Journal of Cancer2019Vol. 113, pp. 72–74
Citations Over TimeTop 17% of 2019 papers
Billal Tedbirt, Michel De Pontville, Pierre Branger, Camille Picard, Barouyr Baroudjian, Célèste Lebbé, Alain Carpentier, Julie Delyon
Related Papers
- → Pembrolizumab‐induced myasthenia gravis with myositis in a patient with lung cancer(2018)36 cited
- → Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer(2018)26 cited
- → Pembrolizumab-Induced Myasthenia Gravis and Myositis: Literature Review on Neurological Toxicities of Programmed Death Protein 1 Inhibitors(2022)14 cited
- → A case of myasthenia gravis and myositis induced by pembrolizumab(2019)8 cited
- → Rippling muscle disease with myasthenia gravis(2022)